A New Era in HIV Treatment Begins Here
First-in-class therapies targeting the core mechanisms of HIV replication.
A New Era in HIV Treatment Begins Here
First-in-class therapies targeting the core mechanisms of HIV replication.
About CureViva Therapeutics
Our Mission
- At CureViva Therapeutics is a biotechnology startup originating from Yale University, focused on developing first-in-class small molecule therapies for HIV. Our lead program targets the Rev-Rev interaction — a novel and essential step in the HIV lifecycle — aiming to block viral replication at its source.
- With a strong foundation in molecular biology, virology, and translational science, we are committed to transforming HIV therapy by addressing unmet clinical needs and drug resistance challenges.
- Our mission is to deliver groundbreaking therapies that bring lasting impact to patients and reshape the future of HIV treatment.
CureViva Science &Technology
Why novel mechanism
Why novel mechanism
Why novel mechanism
Current HIV therapies target viral enzymes or entry pathways, but none address HIV's nuclear RNA export mechanism. Rev is essential for this step.
Mechanism of Action Overview:
- Rev multimerization is essential for HIV RNA transport.
- Our compounds aim to prevent Rev dimerization, blocking viral replication.
Our Expertise
Why novel mechanism
Why novel mechanism
- Our team of scientists and researchers are leaders in the field of biotechnology. We have extensive experience in developing and commercializing cutting-edge biotech products and HIV therapies, and we are constantly exploring new ways to improve patient outcomes.
Our Innovation
Why novel mechanism
Our Innovation
We use a high-throughput, cell-free luciferase assay to identify inhibitors of Rev-Rev interaction—a novel and previously inaccessible therapeutic target.
Impact:
- First-in-class mechanism
- Potential for broad use in resistant patients
- High synergy with existing ART
Welcome to CureViva Therapeutics
At Curviva Therapeutics, we are pioneering a novel class of HIV therapeutics by targeting the Rev protein — a critical mechanism untouched by existing treatments.
Our goal is simple: develop precision therapies that overcome resistance, improve patient outcomes, and lead the way toward long-term viral suppression.